Biotech or Bank?

A look at twenty European biotech companies' cash holdings as a percentage of their market values. Thanks to strengthening investor sentiment in European biotech, certain firms are enjoying bumper years, while others continue to slump with market caps below the value of their cash holdings.

During the depths of the biotech downturn, cash became king. It was by far the strongest acquisition currency, and considered the only asset worth paying for. Last year's battle for Oxford GlycoSciences between Cambridge Antibody Technology Group PLC and UCB Celltech was largely a contest for OGS's cash. It was eventually won in April 2003 by Celltech—which paid cash [See Deal]. (See "OGS: Going, Going, Gone," In Vivo Europe Rx, May 2003 Also see "OGS: Going, Going, Gone" - In Vivo, 1 May, 2003..) Many firms, including OGS, were valued at lower than cash, regardless of the stage or nature of their technologies or drug candidates.

The picture's different today. Thanks to strengthening biotech indices, many of those firms with low cash-as-percentage-of-market value figures are those that have enjoyed overwhelming market support. (See Exhibit 1.) Shares...

More from Global Vision

More from In Vivo